There was also no significant difference in the 5-year survival rates according to intratumoral TS status and UFT-based chemotherapy among stage I adenocarcinomas of the lung (72.2% in UFT-treated patients with TS-negative tumours, 77.2% in UFT-untreated patients with TS-negative tumours, 56.3% in UFT-treated patients with TS-positive tumours, and 66.7% in UFT-untreated patients with TS-positive tumours). Here, TYMS is linked to neoplasm.